References
- Yousefi M, Safari H, Sari AA, et al. Assessing the performance of direct and indirect utility eliciting methods in patients with colorectal cancer: EQ-5D-5L versus C-TTO. Health Serv Outcomes Res Methodol. 2019;19(4):259–270.
- EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.
- Brazier J, Usherwood T, Harper R, et al. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol. 1998;51(11):1115–1128.
- Torrance GW, Furlong W, Feeny D, et al. Multi-attribute preference functions. Pharmacoeconomics. 1995;7(6):503–520.
- Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res. 1988;23(2):203.
- Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med. 2001;33(5):328–336.
- Brazier JE, Mulhern BJ, Bjorner JB, et al., Developing a new version of the SF-6D health state classification system from the SF-36v2: SF-6Dv2. Med Care. 2020;58(6):557–565. .
- Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–292.
- Mulhern BJ, Bansback N, Norman R, et al. Valuing the SF-6Dv2 classification system in the United Kingdom using a discrete-choice experiment with duration. Med Care. 2020;58(6):566–573.
- Poder TG, Fauteux V, He J, et al. Consistency between three different ways of administering the short form 6 dimension version 2. Value Health. 2019;22(7):837–842. .
- Ferreira LN, Ferreira PL, Pereira LN, et al. Exploring the consistency of the SF-6D. Value Health. 2013;16(6):1023–1031. .
- Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12:S5–S9.
- Crawford B, Brazier J, Strand V, et al. Treatment with leflunomide improves the utility of patients with active rheumatoid arthritis: an application of the sf-6d. Value Health. 2001;4(2):70–71.
- Ferreira LN, Ferreira PL, Pereira LN, et al. An application of the SF-6D to create heath values in Portuguese working age adults. J Med Econ. 2008;11(2):215–233.
- Blumenauer B, Cranney A, Clinch J, et al. Quality of life in patients with rheumatoid arthritis. Pharmacoeconomics. 2003;21(13):927–940.
- Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol. 2003;56(4):317–325.
- Kortt MA, Clarke PM. Estimating utility values for health states of overweight and obese individuals using the SF-36. Qual Life Res. 2005;14(10):2177–2185.
- Nahvijou A, Safari H, Ameri H. Comparing the performance of the EQ-5D-5L with two versions of the SF-6Dv2 in patients with breast cancer. Health Serv Outcomes Res Methodol. 2020;20(2):183–94.
- Nahvijou A, Safari H, Yousefi M, et al. Mapping the cancer-specific FACT-B onto the generic SF-6Dv2. Breast Cancer. 2020;1–7.
- Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. John wiley & sons; 2013.
- Harvill LM. Standard error of measurement: an NCME instructional module on. Educ Meas. 1991;10(2):33–41.
- Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42.
- Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003;1(1):4.
- Mukaka MM. A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69–71.
- Ameri H, Yousefi M, Yaseri M, et al. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients. Expert Rev Pharmacoecon Outcomes Res. 2019;19(1):89–96.
- Kiadaliri AA. A comparison of Iran and UK EQ-5D-3L value sets based on visual analogue scale. Int J Health Policy Manag. 2017;6(5):267.
- Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13(9):873–884.
- Green C, Brazier J, Deverill M. Review of health state valuation techniques. Pharmacoeconomics. 2000;17(2):151–165.
- Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5(1):70.